This laboratory has made progress in two general areas: programmatic and specific radioligands.? PROGRAMMATIC.? 1) The Biomarkers Consortium approved the proposal of Victor Pike and me to develop further a PET radioligand for inflammation. The Biomarkers Consortium is a collaboration of NIH, FDA, and the pharmaceutical industry and is managed by the Foundation for NIH. The radioligand labels phagocytic inflammatory cells: macrophages in periphery and activated microglia in the brain. We are now planning specific studies to evaluate and disseminate this radioligand for use in multiple PET Centers.? 2) Dr. Pike (Director of Radiochemistry) and I post our radioligand information on a public web site to assist the PET community. More specifically, we post the IND (Investigation New Drug) application, including toxicology information and detailed chemical synthesis, the FDA review, and our response to review.? 3) I directed an international group of experts to propose a consensus nomenclature for PET imaging, and the resulting paper was recently published. The PET community uses many different terms and abbreviations. This consensus will help clarify terms for the research community.? 4) Dr. Pike and I continue to direct a joint PhD program in neuroscience with NIH and the Karolinska Institutet (Stockholm, Sweden). We now have about 25 graduate students, about half Swedish and half American. Students have two mentors (one from each institution), spend about half time at each institution. The program has been quite successful, and our first class of students is now receiving PhD degrees.? 5) I wish the NIMH PET program to be a national resource to extramural sites. Towards this goal, I established useful collaborations with two nearby institutions in which patients receive state-of-the-art PET scans at NIMH. For example, we are studying a novel radioligand for amyloid in patients with Alzheimer's disease, recruited and studied by Paul Aisen (Georgetown). In addition, Justin McArthur (Johns Hopkins) will soon send patients with neurAIDS to NIMH to be scanned with a novel radioligand for inflammation. If the results are successful, the collaborating institution can use the data as preliminary results in a grant application.? ? ? SPECIFIC RADIOLIGANDS. During the prior year (October 2006 - September 2007), our projects have included:? 1) Development of a probe for Alzheimer's disease. Significant progress has been made to develop a probe that could be used to diagnose and monitor Alzheimer's disease by labeling a protein that accumulates in the brains of patients with this disorder.? ? 2) Evaluation of a probe for intracellular signals. Most of the available probes label targets (or receptors) located on the outside of the cell. We are now examining a probe for an intracellular target (phosphodiesterase) that is believed to be involved in the therapeutic actions of antidepressant treatments.? ? 3) Probe for the cannabinoid receptor, which mediates the effects of marijuana.? ? 4) Probe to measure inflammatory cells. ? ? 5) Probe to measure a transporter pump at the blood-brain barrier.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Intramural Research (Z01)
Project #
1Z01MH002795-06
Application #
7594545
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2007
Total Cost
$1,532,574
Indirect Cost
Name
U.S. National Institute of Mental Health
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Tonietto, Matteo; Veronese, Mattia; Rizzo, Gaia et al. (2015) Improved models for plasma radiometabolite correction and their impact on kinetic quantification in PET studies. J Cereb Blood Flow Metab 35:1462-9
Kimura, Yasuyuki; Siméon, Fabrice G; Zoghbi, Sami S et al. (2012) Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using 18F-SP203. Neuroimage 59:2124-30
Kannan, Pavitra; Brimacombe, Kyle R; Kreisl, William C et al. (2011) Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A 108:2593-8
Kimura, Yasuyuki; Fujita, Masahiro; Hong, Jinsoo et al. (2011) Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. J Nucl Med 52:1638-45
Donohue, Sean R; Dannals, Robert F; Halldin, Christer et al. (2011) N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors. J Med Chem 54:2961-70
Kimura, Yasuyuki; Siméon, Fabrice G; Hatazawa, Jun et al. (2010) Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans. Eur J Nucl Med Mol Imaging 37:1943-9
Skinbjerg, Mette; Liow, Jeih-San; Seneca, Nicholas et al. (2010) D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage 50:1402-7
Lu, Shuiyu; Hong, Jinsoo; Itoh, Tetsuji et al. (2010) [carbonyl-C]Benzyl acetate: automated radiosynthesis via Pd-mediated [C]carbon monoxide chemistry and PET measurement of brain uptake in monkey. J Labelled Comp Radiopharm 53:548-551
Itoh, Tetsuji; Abe, Kohji; Hong, Jinsoo et al. (2010) Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats. Synapse 64:172-6
Ozaki, Harushige; Zoghbi, Sami S; Hong, Jinsoo et al. (2010) In vivo binding of protoporphyrin IX to rat translocator protein imaged with positron emission tomography. Synapse 64:649-53

Showing the most recent 10 out of 75 publications